Navigation Links
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/14/2009

let) has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo(R) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the United States for the treatment of insomnia. Intermezzo(R) uses approximately one-quarter to one-third of the dose of active drug contained in currently marketed zolpidem-based sleep aids, in a formulation designed to promote rapid sublingual absorption. Transcept believes that Intermezzo(R), by combining the reduced zolpidem dose with administration only on those nights when a middle of the night awakening actually occurs, has the potential to reduce unnecessary sedative-hypnotic exposure.

Two Phase 3 clinical studies evaluated 376 patients receiving either Intermezzo(R) or placebo. In the first study, a sleep laboratory trial using an objective polysomnographic endpoint, Intermezzo(R) demonstrated a statistically significant decrease versus placebo in the time it took patients to return to sleep as measured by Latency to Persistent Sleep. In the second study, an outpatient trial, Intermezzo(R) demonstrated a statistically significant decrease in Latency to Sleep Onset, a subjective patient reported endpoint. The most common adverse event seen in these trials was headache (2.7 percent active versus 1.4 percent placebo in the outpatient study).

The FDA has established October 30, 2009 as its target date under PDUFA to take action on its review of the NDA. Transcept is actively pursuing patents to protect Intermezzo(R) in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo(R).

About Transcept

Transcept Pharmaceuticals, Inc.
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
2. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
3. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
4. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
6. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
7. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
9. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
10. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
11. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 28, 2015 The noted Toronto plastic ... Surgery was recently featured in the January/February 2015 issue ... Dr. David Ellis was featured in an article entitled ... cosmetic enhancements that Kim Cattrall has possibly undergone to ... forehead is smooth without horizontal lines or frown line ...
(Date:2/28/2015)... 2015 Plugin creators from Pixel Film ... A fully customizable transition pack made specifically ... gives users total control over 30 transition presets built ... Pixel Film Studios. “TransFold Volume 2 gives endless possibilities ... Volume 2 from Pixel Film Studios brings back folding ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... Health found a correlation between men who cycle on ... for your overall health, the study suggests that the more ... he is to develop prostate cancer, leading to an increased ... important because it allows physicians to look more closely at ...
(Date:2/27/2015)... Bethesda, MD (PRWEB) February 27, 2015 ... Foundation (Meso Foundation) and the National Cancer Institute ... Malignant Mesothelioma at the National Institutes of Health ... parts: one part is dedicated to medical professionals ... other is directed to the general public, including ...
Breaking Medicine News(10 mins):Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3
... Officer of PADRES Contra El Cancer (PADRES), issues a statement ... ... July 8 In response to media reports,suggesting that Univision,s ... media attention to himself, PADRES CEO, Elvia,Barboa, M.A., found it ...
... in Sweden found that more than 40 percent of widowers ... five years earlier reported they were either never told that ... during the last week of her life. Eighty-six percent of ... cancer is incurable, including 71 percent of the men who ...
... announce the arrival of newly FDA-approved Evolence®--the latest injectable collagen ... treatments. EVOLENCE® utilizes highly-purified porcine Type I collagen, regarded as ... similarity to human collagen. , ... ...
... The following statement was issued,today by the law firm ... hereby given that a class action lawsuit was filed in ... on behalf,of all purchasers of securities of Healthways Inc. (Nasdaq: ... through February 26,2008, inclusive (the "Class Period")., If you ...
... Physicians Cite Patient Concerns about Delays in Oxygen ... 8 The new Medicare,competitive bidding program for ... beneficiaries, physicians, hospital discharge,officials, and home medical equipment ... 10 metropolitan areas on July 1., The ...
... The American Society of Hematology (ASH) is proud ... Pathway Grant. The grant is given to training program ... hematology-related training programs. , Thomas Abshire, MD, of ... of Medicine, and David Sternberg, MD, PhD, of Mount ...
Cached Medicine News:Health News:Rumors Dispelled Over Univision Talent Fernando Del Rincon's Cancer Diagnosis Being Fabricated 2Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and t:flex™ ... public offering of 5,250,000 shares of its common stock ... share.  The net proceeds to Tandem from this offering ... discounts and commissions and other estimated offering expenses payable ...
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... , February 26, 2015 ... Outlook 2015: First -In- Class Innovations and Cost ... for Large Cap Pharmaceutical Companies research report to ... According to this Global Pharma US & ... as productivity measurements, divestment of non-core assets result ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4
... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
Near point card/newspaper 8 to 48 point type 5 1/2" X 8"....
It has the near point, Snellen X-CYL Jaeger & SMD cards in one set....
Near point card 4 1/2 to 24 PT 5 1/2" x 8"....
... Eger NP card provides references to many common ... small legal contract size. This provides the examiner ... card is printed with black ink on yellow ... Snellen 20/1000 to 20/20. Other notations include Jaeger, ...
Medicine Products: